According to the New Asia Process announcement, the cumulative deviation value of the company's stock price increase exceeded 20% for two consecutive trading days on July 24 and July 27, 2026, which is an abnormal fluctuation. The company's business does not involve R&D and production of vinyl carbonate, and the lithium hexafluorophosphate business contributes limited to revenue. The company's net profit was negative for three consecutive years from 2023 to 2025, and a net loss of 6 to 12 million yuan is expected in the first half of 2026. The controlling shareholder and its co-actors plan to increase their holdings by 1% to 2% within 6 months. Currently, the total number of pledged shares accounts for 99.24% of their total holdings.

According to the New Asia Process announcement, the cumulative deviation value of the closing price increase of the company's stock exceeded 20% for two consecutive trading days on July 24 and July 27, 2026, which is an abnormal fluctuation. The company's business does not involve R&D and production of vinyl carbonate, and the lithium hexafluorophosphate business contributes limited to revenue. The company's net profit was negative for three consecutive years from 2023 to 2025, and a net loss of 6 to 12 million yuan is expected in the first half of 2026. The controlling shareholder and its co-actors plan to increase their holdings by 1% to 2% within 6 months. Currently, the total number of pledged shares accounts for 99.24% of their total holdings.